November 22, 2026
London, UK

Here is Why Enveric Biosciences ENVB Rallies Today

https://www.uspto.gov/

Enveric Biosciences Inc ENVB trades 95% higher today after the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for a new patent application titled “N-heterocycle substituted tryptamine derivatives and methods of using.”

This patent covers Enveric’s EVM301 Series, including its lead candidate EB-003 (a non-hallucinogenic serotonin receptor agonist in preclinical development for depressive and anxiety disorders).

It includes composition-of-matter and method-of-use claims, potentially expanding the company’s intellectual property to additional neuroplastogenic molecules for treating neuropsychiatric conditions and addiction.

CEO Joseph Tucker commented the development as a key step in “reinforcing our patent estate around our lead asset, EB-003, and the EVM301 Series,” aimed at generating shareholder value.

The stock closed yesterday at $5.24 and now is trading above $11.10. ENVB has a 12-month trading range between $4.88 to $96.30. The stock is down 90% year to date.

In a recent move the company decided the spin-off of its cannabinoid clinical development pipeline to a wholly-owned subsidiary, Akos Biosciences Inc.

Enveric Biosciences Inc. ENVB is a biotechnology company developing neuroplastogenic small-molecule therapeutics for neuropsychiatric disorders like depression, anxiety, and addiction.

Previous Article

Here is why Q/C Technologies QCLS Soars

Next Article

Gemini GEMI Soars After CFTC Aproval for Prediction Markets

You might be interested in …

NIO delivered shares delivery outlook

Nio (NIO) Third Quarter Earnings

Nio reported third-quarter earnings below the analyst’s expectations with wider losses and higher revenues, amid the covid supply disruptions in China.

CVNA Carvana

Here is Why Carvana (CVNA) Stock Collapse

Carvana (CVNA) stock crash continues as the company announced that will lay off 1,500 employees, amid a dismal economic environment that the company failed to predict. The news came as the stock is already down 96% in 2022.